Latest News
Global asset manager Capital Dynamics AG has sold its co-investment in Permasteelisa alongside lead investor Alpha Private Equity Fund 5, realising a multiple of investment cost of three times and a gross IRR of approximately 100%.
The successful exit was achieved by way of a trade sale to JS Group Corporation, a Japanese construction and building materials conglomerate with approximately EUR 8.5 billion in revenues. Completion of the exit took place in December, 2011 following receipt of anti-trust approvals. Permasteelisa is the world’s largest player in the engineering, manufacture and installation of architectural envelopes known as “curtain walls”. The company
The Amplio Group’s solar subsidiary, Amplio Solar, has secured EUR16 million in financing from a leading Italian bank to invest in 7 MW of solar plants in the Italian province of Latina, Lazio. This expansion brings Amplio Solar’s fully operational solar portfolio to over 30 MW, with a total investment to date of approximately EUR120 million.
Amplio Solar has built and project financed the 7 MW of solar plants in Latina, Lazio, with Rios Renovables of Spain as Engineering, Procurement and Construction (“EPC”) contractor. This latest investment underlines a successful 18 months for Amplio Solar, a period in which it
Mid-market private equity firm Palamon Capital Partners has appointed Dr Hans-Joachim Körber to its Board of Advisors.
Dr Körber has had a long and highly distinguished business career including serving as the former President and CEO of METRO AG, one of the largest retailers in the world. He is currently on a number of international boards, including the Boards of Air Berlin PLC and Esprit Holdings Limited on which he is Chairman. In his early career Dr Körber held several senior management positions within the R.A. Oetker Group focusing on IT, logistics, communications and retail. He joined Metro SB Großmärkte in
Stellus Capital Management, a spin off from the D E Shaw Group, has launched as an independent investment firm.
The Stellus team will continue its current strategies of providing secured and unsecured loans to middle market companies and private equity sponsors in a wide range of industries to support growth, leveraged buyouts and refinancings, as well as its current strategies of providing equity and equity-linked debt to the North American energy sector with a focus on the upstream oil and gas segment.
Stellus expects to maintain an ongoing strategic relationship with the D E Shaw group, continue to provide investment advice
The start of this year looks very different to 2011 and 2010 even though the themes and stress points remain the same: Risk is cheaper, non government net issuance is negative, investor allocation to financials and growth related assets is low, another upturn in the global liquidity cycle is starting and Euro break up fears recently hit new highs, according to Graham Neilson, chief investment strategist, Cairn Capital…
Cairn has been taking a more positive tactical slant against a structurally bearish economic and deleveraging backdrop. A number of key catalysts for being more tactically positive fell into place during Q4
CN Creative, Ltd (CNC) has raised GBP2 million (USD3.1 million) in a Series A financing round led by Advent Life Sciences. The funds will be used to continue and finalise development of CNC’s Nicadex, a medically approved, electronic nicotine replacement inhaler.
Despite large-scale public health efforts, about 20% of adults in the UK and the US continue to smoke. Smoking remains the most common cause of preventable death in the Western world and generates enormous costs for healthcare systems worldwide. Two-thirds of smokers report that they would like to quit, and about three-quarters of current smokers say they have tried to
Brian McMahon, Managing Director, Business Development Executive, has been appointed as BNY Mellon’s senior alternative industry facing executive in Luxembourg.
McMahon has particular expertise in private equity and real estate and is also being asked to develop business and relationships for EMEA in PE/RE. He previously held roles at Citi and State Street in investment services.
In addition, the company has promoted Valeria Anderson to Senior Salesperson, Vice President, in the company’s London Alternative Investment Services (AIS) business development team. She has 14 years of experience in financial services, six years of which with BNY Mellon, first in the
Acquisitions of insolvent businesses in the UK have continued to fall in 2011, according to research by Experian on behalf of the insolvency trade body, R3.
The figures show that during 2011, 181 out of a total of 3,146 acquisitions in the UK involved companies acquired out of administration or other formal insolvency procedures – equivalent to one in 17 of all acquisitions. This compares to 2010 when distressed deals accounted for one in 14 acquisitions (216 out of 3,003) and the peak of activity in 2009 when distressed deals represented one in nine of all acquisitions (318 out
Dunedin-backed Hawksford is now the largest independent trust company in Jersey following its acquisition of Trustcorp Jersey Limited (Trustcorp), a Jersey based trust and corporate services provider.
This is the eleventh acquisition made by a Dunedin backed business in the last twelve months and is a prime example of Dunedin’s buy and build strategy of backing businesses with international growth opportunities.
The acquisition forms a significant part of the company’s growth strategy and follows recent expansion into the Middle East and Switzerland. Hawksford opened its Dubai office in June 2011 and acquired L-S&S GmbH, a Zurich boutique private wealth law
Mevion Medical Systems has closed a USD45 Million investment from ProQuest Investments and its existing investors, including Caxton Heath Life Sciences, Venrock and CHL Medical Partners.
Mevion is the manufacturer of the MEVION S250 Proton Therapy System. The capital will be used to accelerate the manufacturing and worldwide deployment of the MEVION S250.
Proton beam radiation therapy permits more precise dose targeting by complete proton absorption at predictable tissue depth, allowing the treatment of target volumes adjacent to critical structures without inadvertent dose to sensitive structures. The availability of proton therapy has remained very limited however, due to the enormous
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
